Please login to the form below

Not currently logged in
Email:
Password:

Cephalon posts record sales

Biopharmaceutical company reports strong second-quarter figures

Cephalon has reported a second-quarter sales increase of 11 per cent to $539m from $485m in Q2 2008, exceeding sales guidance for the period. Adjusted income for the quarter was $110.7m, up 31 per cent on the 2008 second-quarter figure of $84.5m.

The company's figures were bolstered by a strong performance in its oncology franchise where sales increased 86 per cent to $82.2m – figures for Treanda for the treatment of indolent B-cell non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) totalled $55.8m. Sales at Cephalon's central nervous system franchise were also strong rising 16 per cent to $290.6m. In the company's pain division sales fell 8 per cent to $123.6m with growing sales of Amrix largely offsetting the continued generic erosion of Actiq.

The quarter also saw Cephalon launch Nuvigil tablets and file a supplemental new drug application with the US Food and Drug Administration (FDA) for the drug as a treatment for excessive sleepiness associated with jet lag. If Nuvigil is approved it will be the first acute indication for the franchise.

"Nuvigil is off to a great start and in order to serve additional patients we continue to make meaningful progress with our clinical programmes to further develop this product," said Dr Frank Baldino Jr, Cephalon chairman and CEO. "In addition, Treanda and Amrix continue to experience tremendous year-on-year growth. We plan to continue to execute upon our strategy of diversification through our internal discovery and business development activities while delivering solid financial performance," he added.

Cephalon acquired a controlling interest in Australian biotech firm Arana Therapeutics in the second quarter as it continued to build its biotechnology platform. Under the terms of the deal, Cephalon has access to Arana's antibody humanisation and optimisation technology as well as a pipeline of biologics for inflammatory diseases and cancer. 

5th August 2009

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics